SecBot SecBot
PRESS-RELEASE ·Filed Nov 4, 2026

OPK

OPKO Health, Inc.
NEUTRAL
Impact 6/10
Horizonmonths Processed12d 10h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor regulatory approvals and closing timeline for the Labcorp transaction, which will transform OPKO into a pure-play biopharma company. The $125M royalty financing provides near-term liquidity but adds leverage. Watch for Q4 guidance on continuing operations and any updates on ModeX clinical data readouts in H1 2027.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

OPK drug pipeline →

mazdutide

● Neutral Named in this press release
Impact
Phase
Approved (China NMPA)
Time to market
Already approved and commercializing in China (June 2025 for weight management, September 2025 for type 2 diabetes). No US FDA filing has been announced; US approval is estimated in the 2027-2028 window if Eli Lilly initiates and completes global Phase 3 trials.
Next catalyst
None dated

What to watchWatch OPKO's quarterly royalty revenue from mazdutide as a gauge of China commercial uptake. Innovent's product revenue grew over 40% YoY in Q3 2026, but OPKO's specific royalty share is not separately disclosed. No near-term binary catalyst exists for this asset; the next potential catalyst would be Eli Lilly announcing a US Phase 3 program or FDA filing, which is not expected before 2027-2028.

Price Chart

Loading chart...

Executive Summary

OPKO reported Q3 2026 continuing operations revenue of $65.4M (+16% YoY), above the $136.6M consensus which included discontinued diagnostics revenue now reclassified. Net loss from continuing operations was $35.5M ($0.05 per share), versus consensus EPS of -$0.06. The headline event is the agreement to sell substantially all remaining BioReference diagnostic operations to Labcorp for $722M in cash at closing plus up to $150M in contingent consideration, and a $125M senior secured royalty financing with HealthCare Royalty.

Key Financial Metrics

EPS
−$0.05
est −$0.06 · +16.7%
Revenue
$65.4M
est $136.6M · -52.1% · +16.0% YoY
Rating
in line
Guidance
$268M-$278M (continuing ops FY2026)
withdrawn

Key Facts

  • Continuing operations revenue $65.4M, +16% YoY from $56.4M
  • Net loss from continuing operations $35.5M ($0.05 per share) vs consensus -$0.06
  • Agreement to sell substantially all BioReference diagnostic operations to Labcorp for $722M cash at closing plus up to $150M contingent consideration
  • $125M senior secured royalty financing with HealthCare Royalty tied to mazdutide royalty stream
  • Guidance withdrawn for services revenue due to pending Labcorp transaction; product revenue guidance $164M-$169M for FY2026
  • Cash, cash equivalents and restricted cash $403.2M at quarter end
  • Repurchased 7,050,000 shares for ~$10.6M during the quarter

Financial Impact

Continuing ops revenue $65.4M (+16% YoY); net loss $35.5M; Labcorp deal $722M cash + $150M contingent; $125M royalty financing

revenuenet incomecash positiondebt

Segment Breakdown

SegmentRevenueGrowth
Global Products$48.4M+22.8%
Innovative Biotech$17.0M0.0%

Risk Factors

  • Labcorp transaction may not close or may close on less favorable terms
  • Continuing operations still unprofitable with operating loss of $31.4M
  • R&D spending increasing ($30.4M in Q3 2026 vs $26.3M in Q3 2025) with no near-term revenue from pipeline
  • Guidance withdrawn for services revenue creates uncertainty

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
80% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3395883

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026